170 related articles for article (PubMed ID: 16006273)
21. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
22. Aspirin resistance: effect of clinical, biochemical and genetic factors.
Fitzgerald R; Pirmohamed M
Pharmacol Ther; 2011 May; 130(2):213-25. PubMed ID: 21295071
[TBL] [Abstract][Full Text] [Related]
23. Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients.
Derle E; Öcal R; Kibaroğlu S; Çelikkol C; Bayraktar N; Verdi H; Ataç BF; Can U
Blood Coagul Fibrinolysis; 2016 Mar; 27(2):169-75. PubMed ID: 26809135
[TBL] [Abstract][Full Text] [Related]
24. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
25. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism.
Kranzhofer R; Ruef J
Platelets; 2006 May; 17(3):163-9. PubMed ID: 16702043
[TBL] [Abstract][Full Text] [Related]
26. [Cyclooxigenase-1 gene polymorphism and aspirin resistance].
Bondar' TN; Kravchenko NA
Tsitol Genet; 2012; 46(4):66-72. PubMed ID: 23074965
[TBL] [Abstract][Full Text] [Related]
27. [Aspirin resistance theory].
Porosińska A; Pierzchała K
Neurol Neurochir Pol; 2006; 40(4):313-9. PubMed ID: 16967353
[TBL] [Abstract][Full Text] [Related]
28. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms.
Macchi L; Christiaens L; Brabant S; Sorel N; Ragot S; Allal J; Mauco G; Brizard A
J Am Coll Cardiol; 2003 Sep; 42(6):1115-9. PubMed ID: 13678940
[TBL] [Abstract][Full Text] [Related]
29. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
30. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?
Gonzalez-Conejero R; Rivera J; Corral J; Acuña C; Guerrero JA; Vicente V
Stroke; 2005 Feb; 36(2):276-80. PubMed ID: 15604423
[TBL] [Abstract][Full Text] [Related]
31. Aspirin resistance: is this term meaningful?
Violi F; Pignatelli P
Curr Opin Hematol; 2006 Sep; 13(5):331-6. PubMed ID: 16888437
[TBL] [Abstract][Full Text] [Related]
32. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.
Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC
Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970
[TBL] [Abstract][Full Text] [Related]
33. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
[TBL] [Abstract][Full Text] [Related]
34. Aspirin resistance.
Tantry US; Mahla E; Gurbel PA
Prog Cardiovasc Dis; 2009; 52(2):141-52. PubMed ID: 19732606
[No Abstract] [Full Text] [Related]
35. Variability in individual responsiveness to aspirin: clinical implications and treatment.
Coma-Canella I; Velasc A
Cardiovasc Hematol Disord Drug Targets; 2007 Dec; 7(4):274-87. PubMed ID: 18220726
[TBL] [Abstract][Full Text] [Related]
36. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production.
Riondino S; Trifirò E; Principessa L; Mascioletti S; Di Renzo L; Gaudio C; Biasucci LM; Crea F; Pulcinelli FM
Thromb Res; 2008; 122(3):359-65. PubMed ID: 18295304
[TBL] [Abstract][Full Text] [Related]
37. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).
Blais N; Pharand C; Lordkipanidzé M; Sia YK; Merhi Y; Diodati JG
Thromb Haemost; 2009 Aug; 102(2):404-11. PubMed ID: 19652893
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of aspirin resistance.
Patel D; Moonis M
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):969-75. PubMed ID: 17867925
[TBL] [Abstract][Full Text] [Related]
39. [Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action].
Khaspekova SG; Sirotkina OV; Shimanova IuV; Mazurov AV
Biomed Khim; 2008; 54(3):361-71. PubMed ID: 18712091
[TBL] [Abstract][Full Text] [Related]
40. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.
Armstrong PC; Dhanji AR; Truss NJ; Zain ZN; Tucker AT; Mitchell JA; Warner TD
Thromb Haemost; 2009 Oct; 102(4):772-8. PubMed ID: 19806265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
